BBTX
BBTX
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$46.64M
Insider Sales
0
$0
Total Volume
$46.64M
1 transactions
Net Activity
+$46.64M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Ra Capital Management, L.P.
Dir, 10%
$46.64M total
Quick Actions
BBTX has an insider buy conviction of 100%, compared to the Unknown sector buy average of 6%. BBTX ranks #39 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at BBTX (BBTX) engaged in a total of 1 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $46.64M.
The net insider activity for BBTX shows a net buying bias of $46.64M. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Ra Capital Management, L.P. (Dir, 10%), who traded 2.95M shares valued at $46.64M on Oct 30, 2026.
Bambusa Therapeutics: BBTX Stock Price Quote & News
BBTX interactive stock chart | Bambusa Therapeutics, Inc. stock
symbol__ Stock Quote Price and Forecast
Bambusa Therapeutics Ord Shs (BBTX) Earnings Date & Reports & Earnings News
Bambusa Therapeutics prices upsized initial public offering on Nasdaq
Bispecific biotech Bambusa and Parkinson’s-focused Aspen slide on trading debuts
FAQs About BBTX Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for BBTX.